STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of active pharmaceutical ingredients for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidine naloxone for pain; Atorvastatin for elevated cholesterol levels; Pantoprazole for stomach ulcer/reflux; Diclofenac for pain/inflammation; and Enalapril for high blood pressure indications. The Branded Products segment offers APO-Go a Parkinson’s medicine; Aqualor for rhinitis/sore throat; Grippostad a cold medicine; Snup for rhinitis; and Vitaprost for prostate disease indications, as well as Ladival a sun protection product. The company is also involved in the wholesale activities in the pharmaceutical market. It serves patients and/or consumers, doctors, doctors’ cooperatives, pharmacies, pharmacy cooperatives, hospitals, wholesalers, and other service providers in the health care market, as well as public health insurance organizations or private insurances. The company was founded in 1895 and is headquartered in Bad Vilbel, Germany.
Show more
Bad Vilbel, DE
Size (employees)
11,117 (est)
STADA Arzneimittel was founded in 1895 and is headquartered in Bad Vilbel, DE
Report incorrect company information

STADA Arzneimittel Office Locations

STADA Arzneimittel has an office in Bad Vilbel
Bad Vilbel, DE (HQ)
2 Stadastraße
Show all (1)
Report incorrect company information

STADA Arzneimittel Financials and Metrics

STADA Arzneimittel Financials

Market capitalization (30-Oct-2017)

5.1 b

Closing share price (30-Oct-2017)

STADA Arzneimittel's current market capitalization is €5.1 b.
Show all financial metrics
Report incorrect company information